To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

NCT06072131 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

504

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG: Belinostat Injection
DRUG: Pralatrexate Injection
DRUG: CHOP
DRUG: COP

Sponsor

Acrotech Biopharma Inc.